Abstract
Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Graphical Abstract
Current Drug Discovery Technologies
Title:NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease
Volume: 12 Issue: 4
Author(s): C. Subathra Devi, V. Mohanasrinivasan, C. George Priyadoss, Nikhil Arora, Bharti Singh, Neetu Mittal, Shubham Agarwal and Shwetank Saxena
Affiliation:
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Abstract: Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Devi Subathra C., Mohanasrinivasan V., Priyadoss George C., Arora Nikhil, Singh Bharti, Mittal Neetu, Agarwal Shubham and Saxena Shwetank, NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease, Current Drug Discovery Technologies 2015; 12 (4) . https://dx.doi.org/10.2174/1570163813666151117121210
DOI https://dx.doi.org/10.2174/1570163813666151117121210 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pelvic Floor During Pregnancy and after Childbirth, and the Effect of Pelvic Floor Muscle Training on Urinary Incontinence - A Literature Review
Current Women`s Health Reviews Flavonoids in the Treatment of Alzheimer’s and Other Neurodegenerative Diseases
Current Medicinal Chemistry Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Current Alzheimer Research Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus
Current Pharmaceutical Biotechnology Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Properties of CA3 Dendritic Excrescences in Alzheimers Disease
Current Alzheimer Research HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Neuronal Ceroid Lipofuscinosis: The Increasing Spectrum of an Old Disease
Current Molecular Medicine Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals
CNS & Neurological Disorders - Drug Targets The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism